FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

FDA Accepts Pfizer Submissions for Review of Treatment for Rare Amyloid Related Heart Disease

Source: 
CP Wire
snippet: 
  • The tafamidis meglumine form (20 mg capsule) has been granted Priority Review

  • Tafamidis was granted Orphan Drug Designation for ATTR-CM in both the EU and US in 2012